Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

Mallinckrodt and Endo , drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced ...

(Reuters) -All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals, whose medicines are part of the second ...

The pharmaceutical industry is urging the Trump administration and European Union to exclude medical goods from tariff ...

Spring has nearly sprung and round two of the Inflation Reduction Act (IRA)’s negotiation period has begun. | All of the ...

The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their ...

Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people ...

Mallinckrodt and Endo, drugmakers with a shared history of facing bankruptcy and U.S. opioid litigation, have agreed to merge ...

The Department of Health and Human Services (HHS) has filed for summary judgment in its favor regarding lawsuits brought by ...

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York ...

The U.K. government proposes raising mandatory drug rebates paid by drug companies to bolster the National Health Service.

The agency will send an initial offer for each drug with its maximum fair price proposal no later than June 1, and the drugmakers will have 30 days to either accept it or provide a counteroffer.